MediciNova Crescita futura
Future criteri di controllo 0/6
Si prevede che gli utili di MediciNova diminuiranno a una percentuale pari a 6.1% all'anno. Si prevede che l'EPS diminuirà a una percentuale pari a 4.8% all'anno.
Informazioni chiave
-6.1%
Tasso di crescita degli utili
-4.8%
Tasso di crescita dell'EPS
| Biotechs crescita degli utili | 28.3% |
| Tasso di crescita dei ricavi | n/a |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Low |
| Ultimo aggiornamento | 30 Sep 2024 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth
Aug 28
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
Apr 19MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans
Nov 27We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
Jul 11Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation
Mar 18We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth
Oct 12MediciNova to get US patent for MN-166 to treat brain cancer
Sep 15MediciNova's MN-166 to be part of study to treat Long COVID
Aug 16MediciNova begins study of parenteral formulation of MN-166
Jul 22MediciNova announces extension of BARDA contract for Ibudilast development
Jun 30We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
Mar 19MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business
Nov 23MediciNova: The Pain Of A Positive Outlook
Aug 31MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study
Jun 21Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth
May 15The MediciNova Riddle: Worth Unravelling
Apr 26MediciNova inks $20M securities purchase agreement with 3D Investment Partners
Jan 12MediciNova nabs new U.S. patent for ibudilast in multiple sclerosis
Dec 29MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans
Dec 29
Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -12 | N/A | N/A | 1 |
| 12/31/2025 | N/A | -12 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -11 | N/A | N/A | 1 |
| 9/30/2024 | N/A | -10 | -9 | -9 | N/A |
| 6/30/2024 | 1 | -8 | -9 | -9 | N/A |
| 3/31/2024 | 1 | -8 | -8 | -8 | N/A |
| 12/31/2023 | 1 | -9 | -7 | -7 | N/A |
| 9/30/2023 | 1 | -10 | -11 | -11 | N/A |
| 6/30/2023 | N/A | -12 | -12 | -12 | N/A |
| 3/31/2023 | N/A | -14 | -12 | -12 | N/A |
| 12/31/2022 | N/A | -14 | -13 | -13 | N/A |
| 9/30/2022 | N/A | -13 | -13 | -13 | N/A |
| 6/30/2022 | 0 | -13 | -13 | -13 | N/A |
| 3/31/2022 | 0 | -13 | -9 | -9 | N/A |
| 12/31/2021 | 4 | -10 | -9 | -9 | N/A |
| 9/30/2021 | 4 | -11 | -8 | -8 | N/A |
| 6/30/2021 | 4 | -11 | -9 | -9 | N/A |
| 3/31/2021 | 4 | -11 | -12 | -12 | N/A |
| 12/31/2020 | N/A | -14 | -11 | -11 | N/A |
| 9/30/2020 | N/A | -13 | -11 | -11 | N/A |
| 6/30/2020 | N/A | -12 | -9 | -9 | N/A |
| 3/31/2020 | N/A | -11 | -9 | -9 | N/A |
| 12/31/2019 | N/A | -13 | -9 | -9 | N/A |
| 9/30/2019 | N/A | -11 | -8 | -8 | N/A |
| 6/30/2019 | N/A | -16 | -8 | -8 | N/A |
| 3/31/2019 | N/A | -15 | -8 | -8 | N/A |
| 12/31/2018 | N/A | -15 | -9 | -9 | N/A |
| 9/30/2018 | N/A | -16 | -9 | -9 | N/A |
| 6/30/2018 | N/A | -13 | N/A | -9 | N/A |
| 3/31/2018 | N/A | -13 | N/A | -8 | N/A |
| 12/31/2017 | N/A | -11 | N/A | -7 | N/A |
| 9/30/2017 | N/A | -11 | N/A | -7 | N/A |
| 6/30/2017 | N/A | -10 | N/A | -7 | N/A |
| 3/31/2017 | N/A | -11 | N/A | -7 | N/A |
| 12/31/2016 | N/A | -11 | N/A | -7 | N/A |
| 9/30/2016 | N/A | -12 | N/A | -7 | N/A |
| 6/30/2016 | N/A | -11 | N/A | -7 | N/A |
| 3/31/2016 | N/A | -10 | N/A | -6 | N/A |
| 12/31/2015 | N/A | -9 | N/A | -7 | N/A |
| 9/30/2015 | N/A | -8 | N/A | -7 | N/A |
| 6/30/2015 | N/A | -9 | N/A | -7 | N/A |
| 3/31/2015 | N/A | -9 | N/A | -7 | N/A |
| 12/31/2014 | N/A | -9 | N/A | 1 | N/A |
| 9/30/2014 | 6 | -3 | N/A | -2 | N/A |
| 6/30/2014 | 6 | -3 | N/A | -2 | N/A |
| 3/31/2014 | 6 | -4 | N/A | -3 | N/A |
| 12/31/2013 | 6 | -4 | N/A | -11 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che MNOV rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che MNOV rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che MNOV rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di MNOV cresceranno più rapidamente del mercato US.
Ricavi ad alta crescita: Si prevede che MNOV non avrà alcun fatturato il prossimo anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di MNOV è previsto essere elevato tra 3 anni